Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

JAGX vs PTN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

PTN Overall Winner 6-Pillar Tally: JAGX 2 – 3 PTN (1 Tie) Matrix Metrics: JAGX 3 – 6 PTN

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Jaguar Health, Inc. (JAGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). JAGX carries a Unified Composite Score of 54.5/100 (HOLD) at $0.39 (N/M Forward P/E, -90.2% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin).

  • Composite vs. Pillar Nuance: While JAGX currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -90.2% operating margin) and revenue trajectory (-80.1% vs. -58.9% YoY).
  • Technical & Structure Timing Caution: JAGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.8); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About JAGX vs PTN
JAGX NASDAQ
Jaguar Health, Inc.
Pharmaceutical Preparations
$0.39
-7.74% 1D
Market Cap $5.6M
TTM Revenue $28M
Forward P/E N/M
Beta / 30D Vol 30.19β · 228% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $1.24 · SMA50: $3.31
PTN US Equity Head-to-Head Winner
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07

6-Pillar Scorecard Institutional Category Breakdown (JAGX 2 – 3 PTN)

Columns: Metric · JAGX · PTN
1. Valuation Multiples PTN
Forward P/E N/M 42.9x
Trailing P/E N/M 42.9x
PEG Ratio N/M 1.62x
EV / Revenue 0.7x 0.1x
2. Growth & Scale JAGX
Revenue Growth (YoY) -58.9% -80.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28M $13M
Market Cap $5.6M $11.1M
3. Profitability & Quality PTN
Gross Margin 82.3% 6.2%
Operating Margin -90.2% -65.7%
Net Profit Margin -130.8% -63.5%
Return on Equity (ROE) -548.8% -877.5%
4. Balance Sheet & Cash Flow JAGX
Cash Generation (TTM) -$6.7M -$15M
Cash Flow Margin -24.2% -113.6%
Net Cash / Leverage $15M Net Debt (2.77x D/E) $9.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity N/A 71.9% of Rev ($9.5M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: JAGX (3) vs PTN (6)
Institutional Metric JAGX PTN Criterion Row Edge
Market Capitalization
Scale
$5.6M $11.1M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Forward P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY)
Growth
-58.9% -80.1% Higher Growth JAGX
Operating Margin (TTM)
Profitability
-90.2% -65.7% Higher Margin PTN
Net Profit Margin
Profitability
-130.8% -63.5% Higher Margin PTN
Return on Equity (ROE)
Capital Efficiency
-548.8% -877.5% Higher ROE JAGX
52-Week Range Position
Momentum
0% ($0–$42) 6% ($5–$31) Stronger Trend PTN
Beta / 30D Volatility
Risk Regime
30.19β · 228% Vol 0.87β · 106% Vol Lower Realized Risk PTN
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite JAGX
Trailing 12M Revenue (USD)
Operating Scale
$28M $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
82.3% 6.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev 1.62x PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.7M ($15M Net Debt (2.77x D/E)) -$15M ($9.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +90.78 pp
JAGX: -89.04% · PTN: +1.74%
3M Horizon PTN +18.71 pp
JAGX: -60.43% · PTN: -41.72%
6M Horizon PTN +29.75 pp
JAGX: -89.56% · PTN: -59.81%
1Y Horizon PTN +33.98 pp
JAGX: -77.27% · PTN: -43.29%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period JAGX Revenue PTN Revenue JAGX Op. Margin PTN Op. Margin Margin Leader
FY2019 $10M $60M -501.3% 59.3% PTN
FY2020 $10M $0M -283.9% -20007.6% JAGX
FY2021 $0M N/A -939.1% N/A JAGX
FY2022 $10M $0M -287.8% -2491.6% JAGX
FY2023 $10M $0M -351.3% -668.7% JAGX
FY2024 $10M $0M -263.8% -501.0% JAGX
FY2025 $10M N/A -398.8% N/A JAGX
FY2026 N/A $10M N/A -65.7% PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
JAGX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact JAGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
JAGX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.6M market capitalization and -90.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published

Investor FAQ JAGX vs PTN Key Questions & Quantitative Answers

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Jaguar Health, Inc. (JAGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). JAGX carries a Unified Composite Score of 54.5/100 (HOLD) at $0.39 (N/M Forward P/E, -90.2% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin). Composite vs. Pillar Nuance: While JAGX currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -90.2% operating margin) and revenue trajectory (-80.1% vs. -58.9% YoY). Technical & Structure Timing Caution: JAGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.8); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

JAGX leads the Growth & Scale pillar: JAGX posts -58.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (82.3% gross margin, -90.2% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), JAGX cumulative revenue shifted +0.0% while PTN shifted -83.3%. In operating R&D and SG&A reinvestment, JAGX deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.

PTN screens cheaper on headline valuation multiples. JAGX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-24.2% FCF margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JAGX (-548.8% ROE) versus PTN (-877.5% ROE) capital efficiency.

In options market volatility and institutional positioning, JAGX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (30.19β · 228% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.